The Effect of Decitabine Dose Modification and Myelosuppression on Response and Survival in Patients With Myelodysplastic Syndromes

Myelosuppression in myelodysplastic syndromes (MDS) is associated with the hypomethylating agent decitabine. A retrospective pooled analysis of 2 decitabine clinical trials in patients with MDS conducted Cox regression analyses of red blood cell or platelet dependence, myelosuppression, dose modific...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Leuk Lymphoma
Autores principales: Jabbour, Elias, Garcia-Manero, Guillermo, Cornelison, A. Megan, Cortes, Jorge E., Ravandi, Farhad, Daver, Naval, Kadia, Tapan, Teng, Angela, Kantarjian, Hagop
Formato: Artigo
Lenguaje:Inglês
Publicado: 2014
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4297591/
https://ncbi.nlm.nih.gov/pubmed/24844364
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2014.914192
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares